Abstract:Background A limited amount of information is available about the immunogenicity of the quadrivalent inactivated influenza vaccine among human immunodeficiency virus (HIV)-infected individuals, especially in low and middle-income countries (LMICs). Methods HIV-infected adults and HIV-uninfected adults received a dose of quadrivalent inactivated influenza vaccine including strains of H1N1, H3N2, BV and BY. Enzyme-linked immunosorbent assay (ELISA) and hemagglutination-inhibition assay (HAI) were used to determine IgA, IgG antibody concentration and geometric mean titers (GMT) at day 0 and day 28, respectively. Associated factors contributing to seroconversion or GMT changes were analyzed using simple logistic regression model. Results A total of 131 HIV-infected and 55 HIV-uninfected subjects were included in the study. In both HIV-infected and uninfected arms, IgG and IgA against influenza A and B all increased significantly at day 28 after receiving QIV (P < 0.001). GMTs of post-vaccination at day 28 showed that HIV-infected persons with CD4 + T cell counts ≤ 350 cells/mm 3 were statistically less immunogenic to all strains of QIV than HIV-uninfected ones (P < 0.05). HIV-infected participants with CD4 + T cell counts ≤ 350 cells/mm 3 were less likely to achieve seroconversion to QIV (H1N1, BY and BV) than HIV-uninfected individuals at day 28 after vaccination ( P < 0.05). Compared with HIV-infected patients with baseline CD4 + T cell counts ≤ 350 cells/mm 3 , individuals with baseline CD4 + T cell counts > 350 cell/mm 3 seemed more likely to generate antibody responses to H1N1 (OR:2.65, 95 %CI: 1.07–6.56) and BY (OR: 3.43, 95 %CI: 1.37–8.63), and showed a higher probability of seroconversion to BY (OR: 3.59, 95 %CI: 1.03–12.48). Compared with nadir CD4 + T cell count ≤ 350 cell/mm 3 , individuals with nadir CD4 + T cell count > 350 cell/mm 3 showed a higher probability of seroconversion to H1N1(OR: 3.15, 95 %CI: 1.14–8.73). Conclusion Influenza vaccination of HIV-infected adults might be effective despite variable antibody responses. HIV-positive populations with CD4 + T cell counts ≤ 350 are less likely to achieve seroconversion. Further vaccination strategies could be developed for those with low CD4 T cell counts.

Attenuation of hepatitis A antibody after immunization with hepatitis A vaccine (Aimmugen) in people living with HIV

The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective Study

Long-term Persistence of Anti-Hav Antibody Conferred by a Single Dose of Live-Attenuated Hepatitis A Vaccine: Results from 17-Year Follow-Up.

Persistence of Anti-HAV Antibody and Long-Term Protection Conferred by a Single Dose of Live-Attenuated Hepatitis a Vaccine: Results from 17-Year Follow-Up

Extending the Dosing Interval of COVID-19 Vaccination Leads to Higher Rates of Seroconversion in People Living with HIV.

Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up.

Immune Memory at 17-Years of Follow-Up of a Single Dose of Live Attenuated Hepatitis A Vaccine.

Low rate of vaccination and risk of incident hepatitis A among HIV-infected men who have sex with men in Seville, Southern Spain

Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects

HIV viraemia during hepatitis B vaccination shortens the duration of protective antibody levels

[Immunogenicity and Efficacy of Two Live Attenuated Hepatitis A Vaccines (H(2) Strains and LA-1 Strains)].

Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults

[Safety and Immunogenicity of a New Inactivated Hepatitis A Vaccine].

Safety and Immunogenicity of a New Inactivated Hepatitis A Vaccine

Factors Associated with Neutralizing Antibody Responses following 2-Dose and 3rd Booster Monovalent COVID-19 Vaccination in Japanese People Living with HIV

Human Papillomavirus Antibody Levels Following Vaccination or Natural Infection among Young Men Who Have Sex with Men

Correction To: Human Papillomavirus Antibody Levels Following Vaccination or Natural Infection among Young Men Who Have Sex with Men.

Immune response to one booster dose of inactivated hepatitis A vaccine in college students

Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial

Comparison Of Immunogenicity Between Inactivated And Live Attenuated Hepatitis A Vaccines Among Young Adults: A 3-Year Follow-Up Study

A 3-Year Observation on Antibody of Large-Scale Immunization with a Live Attenuated Hepatitis A Vaccine (LA-1 Strain)